Rare Diseases
Build on our experience of more than 245 rare disease studies in 96 countries to fulfill your promise of hope to millions around the world.
-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Global Public Health
- Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSFEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI™
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience Solutions with Apple devices
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Public Health
- Code of Conduct
- Environmental Social Governance
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions with Apple devices
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREWORKING AT IQVIA
Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORELIFE AT IQVIA
Careers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
WE’RE HIRING
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSWhite Paper
Registries for Rare Diseases
A foundation for multi-arm, multi-company trials
Jan 15, 2019
Through recent collaborative efforts, the FDA and EMA are hoping to encourage multi-arm, multi-company clinical trials for pediatric rare diseases. This white paper examines how registries can provide a valuable foundation for these types of trials by fostering long-term, collaborative relationships between rare disease stakeholders and improving our understanding of diseases and treatment outcomes.
IntroductionIn July 2017, the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) published a joint proposal on multi-arm, multi-company clinical trials, which would use a single control arm to compare multiple medicines.1 The proposal – focusing on Gaucher disease, but intended as a general roadmap for pediatric rare diseases – would allow for economies of scale as multiple sponsors could share the responsibility and cost of identifying and recruiting patients. This guidance does not eliminate any of the existing requirements for rare disease drug development; however, the FDA and EMA may exercise flexibility in determining the kind and quantity of data required to meet the statutory standard.
The approach could enable a better determination of relative risk-benefit by increasing the quantity and quality of safety and effectiveness data; and lead to smoother regulatory pathways, as regulators incentivize sponsors to consider these trials. While there are significant hurdles to the proposed approach, collaborative efforts to develop registries could be seen as a positive step in the process of multi-company cooperation in rare disease research.
THE PROMISE OF REGISTRIES
Rare disease registries typically have the following objectives:
- To connect patients, their caregivers and clinicians
- To better understand the natural history and outcomes of the rare disease
- To support research on the genetic, molecular and physiological basis of the disease
- To establish a patient base for evaluating potential therapies and medical devices.
Data from registries can significantly benefit early-stage drug development, and potentially serve as a starting point for multi-arm, multi-company clinical trials. Registries can help address many challenges inherent in rare disease trials, allowing for a more complete understanding of the disease course and variability; guiding the development of endpoint measures, patient reported outcomes (PROs) and biomarkers; facilitating feasibility assessments for future trials; providing a source of patients for clinical trials; and gathering longer term safety and efficacy data after registration trials are completed.
Rare disease registries can also improve clinical trial design by providing information on disease natural history, informing sample size calculations, being used as a historical control group for post-marketing monitoring,5 or for examining real-life outcomes data from different treatment regimens globally.
SUCCESSFUL ONGOING INITIATIVES
Disease-focused, not-for-profit foundations and patient advocacy groups have a proven track record of operating registries in the public interest and can serve as models for future collaborations. Sponsors work in parallel to access specific data sets relevant to their R&D assets, helping to inform clinical development without disclosing commercially sensitive information. This may form the basis for future collaboration between sponsors on multi-company, multi-arm trials.
DOWNLOAD TO LEARN MORE
Related solutions
Clinical Trials
Change the model of clinical research by integrating data, expertise, analytics and technology from study design through execution to power better decisions.